---
schema_version: "secwatch.filing_event.v1"
accession: "0001785530-23-000016"
form_type: "8-K"
ticker: "HOWL"
cik: "0001785530"
company_name: "Werewolf Therapeutics, Inc."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T04:30:44.453314+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Werewolf Therapeutics Q1 net loss $12.0M; COO retiring; WTX-124 data expected 4Q23

## Summary
- Net loss of $12.0M improved from $15.3M in Q1 2022; cash and equivalents $147.9M.
- Collaboration revenue of $4.5M from Jazz Pharma licensing agreement; R&D spend $11.7M.
- COO Reid Leonard retiring effective June 30, 2023; founding executive team member.
- Phase 1/1b WTX-124 monotherapy data (safety, tolerability, efficacy) expected 4Q 2023.
- New candidate WTX-712 (IL-21 INDUKINE) preclinical data presented at AACR 2023.

## SEC filing metadata
- accession: 0001785530-23-000016
- form_type: 8-K
- ticker: HOWL
- cik: 0001785530
- company_name: Werewolf Therapeutics, Inc.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1785530/000178553023000016/0001785530-23-000016-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1785530/000178553023000016/howl-20230511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001785530-23-000016
- JSON: https://secwatch.observer/filing/0001785530-23-000016.json
- Plain text: https://secwatch.observer/filing/0001785530-23-000016.txt

## Key facts
- Earnings Releases
  Werewolf Therapeutics, Inc. reported the first quarter ended March 31, 2023 results: revenue Collaboration revenue was $4.5 million.
  - Period: the first quarter ended March 31, 2023
  - Revenue: Collaboration revenue was $4.5 million
  - Result: reported results
  source text: sufficient to fund its operational expenses and capital expenditure requirements through at least the fourth quarter of 2024. • Collaboration revenue: Collaboration revenue was $4.5 million for the first quarter of 2023, compared to zero for the same period in 2022. Collaboration revenue is related to partial recognition of the $15.0 million upfront payment received
  evidence_url: https://www.sec.gov/Archives/edgar/data/1785530/000178553023000016/0001785530-23-000016-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.